Mesoblast Limited vs iShares TIPS Bond ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while iShares TIPS Bond ETF trades at $107.92. The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| MESO | TIP | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Fixed Income |
52-Week High | $20.96 | $112.20 |
52-Week Low | $12.88 | $107.91 |
Enterprise Value | $2.17B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TIP trades at $108.05, down 0.2% today, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The stock lacks disclosed valuation metrics like P/E and P/S, and recent news highlights bond market volatility and Federal Reserve uncertainty influencing investor sentiment. Dividend payments are scheduled for 2026, providing income visibility.
Outlook is cautious due to bearish technical signals and macroeconomic risks from potential Fed rate hikes. Investment opportunities include dividend income, but risks involve market volatility and lack of current fundamental data. Investors should await earnings reports for clarity on financial health.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →